TPLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL

被引：0
|
作者：
Hopfinger, Georg [1 ]
Busch, Raymond [2 ]
Barbara, Eichhorst [3 ]
Paula, Cramer [3 ]
Gabriele, Kandler [1 ]
Gunther, Fingerle-Rowson [3 ]
Anna-Maria, Fink [3 ]
Stephan, Stilgenbauer [4 ]
Michael, Hallek [3 ]
机构：
[1] Hanusch Hosp, Dept Med 3, Vienna, Austria
[2] Tech Univ Munich, Inst Med Stat, D-8000 Munich, Germany
[3] Klinik 1, Cologne, Germany
[4] Klinik 3, Ulm, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2039
引用
收藏
页码：607A / 607A
页数：1
相关论文
共 25 条
  • [21] CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Duehrsen, U
    Schulz, H
    Wendtner, CM
    Goebeler, ME
    Hallek, M
    BLOOD, 2005, 106 (11) : 601A - 601A
  • [22] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2011, 118 (21) : 136 - 137
  • [23] Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen
    Fischer, Kirsten
    Bahlo, Jasmin
    Fink, Anna-Maria
    Busch, Raymonde
    Boettcher, Sebastian
    Mayer, Jiri
    Dreger, Peter
    Maurer, Christian
    Engelke, Anja
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2012, 120 (21)
  • [24] CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1):: Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL.
    Trumper, L. H.
    Hohloch, K.
    Kloess, M.
    Duehrsen, U.
    Eimermacher, H.
    Haas, A.
    Aldaoud, A.
    Loeffler, M.
    Schmitz, N.
    Pfreundschuh, M.
    Binder, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 431S - 431S
  • [25] Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group
    Al-Sawaf, Othman
    Ligtvoet, Rudy
    Robrecht, Sandra
    Stumpf, Janina
    Fink, Anna Maria
    Tausch, Eugen
    Schneider, Christof
    Boettcher, Sebastian
    Mikusko, Martin
    Ritgen, Matthias
    Schetelig, Johannes
    Von Tresckow, Julia
    Vehling-Kaiser, Ursula
    Wendtner, Clemens-Martin
    Fischer, Kirsten
    Kreuzer, Karl Anton
    Stilgenbauer, Stephan
    Staber, Philipp Bernhard
    Niemann, Carsten Utoft
    Hallek, Michael
    Eichhorst, Barbara F.
    BLOOD, 2023, 142
123